MEDNAX (NYSE:MD) had its price target increased by equities researchers at BMO Capital Markets from $46.00 to $58.00 in a research report issued to clients and investors on Monday, February 12th. The brokerage presently has a “market perform” rating on the stock. BMO Capital Markets’ price objective points to a potential upside of 0.85% from the stock’s current price.
Several other equities analysts have also recently weighed in on MD. KeyCorp set a $51.00 price objective on shares of MEDNAX and gave the stock a “buy” rating in a research note on Wednesday, November 1st. Jefferies Group restated a “hold” rating and set a $44.00 target price on shares of MEDNAX in a research note on Friday, November 3rd. Robert W. Baird raised their target price on shares of MEDNAX from $47.00 to $48.00 and gave the stock a “neutral” rating in a research note on Friday, November 3rd. Citigroup decreased their target price on shares of MEDNAX from $52.00 to $47.00 and set a “neutral” rating on the stock in a research note on Friday, November 3rd. Finally, Piper Jaffray Companies initiated coverage on shares of MEDNAX in a research note on Wednesday, December 13th. They set an “overweight” rating and a $58.00 target price on the stock. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and four have assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $54.92.
MEDNAX (NYSE:MD) opened at $57.51 on Monday. MEDNAX has a one year low of $40.56 and a one year high of $72.13. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 0.60. The firm has a market cap of $5,404.50, a P/E ratio of 16.67, a PEG ratio of 1.43 and a beta of 0.31.
MEDNAX (NYSE:MD) last issued its quarterly earnings data on Thursday, February 8th. The company reported $0.87 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.83 by $0.04. MEDNAX had a net margin of 9.26% and a return on equity of 10.10%. The firm had revenue of $910.82 million for the quarter, compared to analysts’ expectations of $884.55 million. During the same quarter in the prior year, the business earned $1.00 EPS. The business’s quarterly revenue was up 9.6% on a year-over-year basis. research analysts expect that MEDNAX will post 4.03 earnings per share for the current fiscal year.
In other MEDNAX news, insider John C. Pepia sold 3,000 shares of the stock in a transaction that occurred on Tuesday, December 12th. The shares were sold at an average price of $51.58, for a total transaction of $154,740.00. Following the completion of the sale, the insider now directly owns 35,569 shares of the company’s stock, valued at approximately $1,834,649.02. The sale was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 2.40% of the company’s stock.
A number of institutional investors and hedge funds have recently made changes to their positions in MD. QS Investors LLC grew its holdings in MEDNAX by 0.3% during the 2nd quarter. QS Investors LLC now owns 3,812 shares of the company’s stock valued at $230,000 after buying an additional 12 shares in the last quarter. Nomura Holdings Inc. purchased a new position in shares of MEDNAX in the second quarter valued at $347,000. Verition Fund Management LLC purchased a new position in shares of MEDNAX in the second quarter valued at $516,000. Lord Abbett & CO. LLC purchased a new position in shares of MEDNAX in the second quarter valued at $14,346,000. Finally, Mutual of America Capital Management LLC grew its holdings in shares of MEDNAX by 3.2% in the third quarter. Mutual of America Capital Management LLC now owns 77,239 shares of the company’s stock valued at $3,331,000 after purchasing an additional 2,422 shares in the last quarter. 95.12% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: This piece was first reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this piece can be viewed at https://www.thelincolnianonline.com/2018/02/23/mednax-md-pt-raised-to-58-00.html.
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.